Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension

Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway. Lupin’s Apixaban Oral Suspension 1.25 mg/mL is an oral […]